Anti-inflammatory strategies for atherosclerotic artery disease
- 2 March 2022
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 21 (5) , 661-672
Abstract
Atherosclerosis is the most frequent cause of coronary artery disease (CAD) and inflammation is a key driver of its pathogenesis. Targeting inflammation represents a novel therapeutic option beyond...Keywords
This publication has 109 references indexed in Scilit:
- Effects of Interleukin-1 Blockade With Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]The American Journal of Cardiology, 2013
- Group X Secreted Phospholipase A2 Limits the Development of Atherosclerosis in LDL Receptor–Null MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2013
- C-Reactive Protein, Fibrinogen, and Cardiovascular Disease PredictionNew England Journal of Medicine, 2012
- The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysisThe Lancet, 2012
- Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studiesThe Lancet, 2012
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque developmentNature Medicine, 2008
- Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic MechanismsNature Reviews Drug Discovery, 2005
- Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain 1 1Edited by F. E. CohenJournal of Molecular Biology, 1999
- Regulation of the mevalonate pathwayNature, 1990